Peptides get their regulatory closeup

Key Points:

• The FDA is holding a two-day advisory committee meeting to consider whether compounding pharmacies should be allowed to produce seven popular injectable peptides, including TB-500, BPC-157, and MOTs-C, despite limited clinical trial data on their safety and effectiveness.
• Peptides have gained widespread popularity in the wellness and longevity sectors for benefits like injury recovery, muscle growth, and metabolism, with many telehealth companies and clinics marketing these therapies even as scientific evidence remains sparse.
• Industry advocates argue that current restrictions have driven demand underground, leading to unregulated and potentially unsafe peptide use, while FDA career scientists recommend against approving compounding of these peptides due to insufficient human data.
• The advisory committee includes new members with ties to the peptide industry, reflecting ongoing tensions between Health Secretary Robert F. Kennedy Jr.'s pro-peptide stance and traditional medical authorities, raising concerns about regulatory impartiality.
• Experts caution that while some real-world experience suggests potential benefits, the lack of rigorous clinical trials and risks such as cancer promotion or immune reactions warrant careful consideration before expanding access to compounded peptides.